IMM News: Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Brea - 18th Mar 2022, 11:00pm

[annb0t]

Immutep Limited

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022.

Immutep’s AIPAC trial evaluated its lead product candidate eftilagimod alpha (“efti”) in combination with ...

>>> Read more: Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022